Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1;12(3):e0172564.
doi: 10.1371/journal.pone.0172564. eCollection 2017.

The reporting of study and population characteristics in degenerative cervical myelopathy: A systematic review

Benjamin M Davies  1 , M McHugh  1 , A Elgheriani  2 , Angelos G Kolias  1   3 , Lindsay Tetreault  2 , Peter J A Hutchinson  1   4 , Michael G Fehlings  2 , Mark R N Kotter  1   2   3   4
Affiliations

The reporting of study and population characteristics in degenerative cervical myelopathy: A systematic review

Benjamin M Davies et al. PLoS One. .

Abstract

Object: Degenerative cervical myelopathy [DCM] is a disabling and increasingly prevalent condition. Variable reporting in interventional trials of study design and sample characteristics limits the interpretation of pooled outcomes. This is pertinent in DCM where baseline characteristics are known to influence outcome. The present study aims to assess the reporting of the study design and baseline characteristics in DCM as the premise for the development of a standardised reporting set.

Methods: A systematic review of MEDLINE and EMBASE databases, registered with PROSPERO (CRD42015025497) was conducted in accordance with PRISMA guidelines. Full text articles in English, with >50 patients (prospective) or >200 patients (retrospective), reporting outcomes of DCM were deemed to be eligible.

Results: A total of 108 studies involving 23,876 patients, conducted world-wide, were identified. 33 (31%) specified a clear primary objective. Study populations often included radiculopathy (51, 47%) but excluded patients who had undergone previous surgery (42, 39%). Diagnositic criteria for myelopathy were often uncertain; MRI assessment was specified in only 67 (62%) of studies. Patient comorbidities were referenced by 37 (34%) studies. Symptom duration was reported by 46 (43%) studies. Multivariate analysis was used to control for baseline characteristics in 33 (31%) of studies.

Conclusions: The reporting of study design and sample characteristics is variable. The development of a consensus minimum dataset for (CODE-DCM) will facilitate future research synthesis in the future.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow diagram of search strategy.
See this image and copyright information in PMC

References

    1. Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative Cervical Myelopathy: Epidemiology, Genetics, and Pathogenesis. Spine. 2015;40: E675–93. 10.1097/BRS.0000000000000913 - DOI - PubMed
    1. Karadimas SK, Gatzounis G, Fehlings MG. Pathobiology of cervical spondylotic myelopathy. Eur Spine J. 2015;24 Suppl 2: 132–138. - PubMed
    1. Davies BM, McHugh M, Elgheriani A, Kolias AG, Tetreault LA, Hutchinson PJA, et al. Reported Outcome Measures in Degenerative Cervical Myelopathy: A Systematic Review. PLoS ONE. 2016;11: e0157263 10.1371/journal.pone.0157263 - DOI - PMC - PubMed
    1. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino M-A, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67: 745–753. 10.1016/j.jclinepi.2013.11.013 - DOI - PubMed
    1. Tetreault LA, Karpova A, Fehlings MG. Predictors of outcome in patients with degenerative cervical spondylotic myelopathy undergoing surgical treatment: results of a systematic review. Eur Spine J. Springer Berlin Heidelberg; 2013;24: 236–251. - PubMed

Publication types

MeSH terms